

# Todd Kelley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4129303/publications.pdf>

Version: 2024-02-01

55  
papers

2,497  
citations

331670

21  
h-index

233421

45  
g-index

55  
all docs

55  
docs citations

55  
times ranked

3129  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Engineering Design in Technology Education. Contemporary Issues in Technology Education, 2022, , 133-147.	0.5	4
2	STEM Integration through shared practices: examining secondary science and engineering technology studentsâ€™ concurrent think-aloud protocols. Journal of Engineering Design, 2022, 33, 343-365.	2.3	7
3	Increasing high school teachers self-efficacy for integrated STEM instruction through a collaborative community of practice. International Journal of STEM Education, 2020, 7, .	5.0	72
4	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 2020, 34, 2981-2991.	7.2	8
5	Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness. Archives of Pathology and Laboratory Medicine, 2019, 143, 105-111.	2.5	3
6	Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia. Experimental Hematology, 2019, 76, 38-48.e2.	0.4	11
7	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell, 2019, 36, 431-443.e5.	16.8	137
8	Influence of sketching instruction on elementary studentsâ€™ design cognition: a study of three sketching approaches. Journal of Engineering Design, 2019, 30, 199-226.	2.3	16
9	Nuclearâ€™Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clinical Cancer Research, 2019, 25, 2323-2335.	7.0	24
10	Genome-Wide Copy Number Variation Detection Using NGS: Data Analysis and Interpretation. Methods in Molecular Biology, 2019, 1908, 113-124.	0.9	17
11	Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants. Blood, 2019, 134, 188-188.	1.4	2
12	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
13	Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget, 2018, 9, 17889-17894.	1.8	1
14	Sketching by design: teaching sketching to young learners. International Journal of Technology and Design Education, 2017, 27, 363-386.	2.6	22
15	Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia. Leukemia Research, 2017, 56, 7-12.	0.8	51
16	Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts. Methods in Molecular Biology, 2017, 1633, 151-161.	0.9	6
17	Examining Elementary School Studentsâ€™ Transfer of Learning Through Engineering Design Using Think-Aloud Protocol Analysis. Journal of Technology Education, 2017, 28, .	0.8	16
18	Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. British Journal of Haematology, 2016, 173, 49-58.	2.5	27

#	ARTICLE	IF	CITATIONS
19	Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (<i>BCR-ABL1</i>). Archives of Pathology and Laboratory Medicine, 2016, 140, 672-674.	2.5	1
20	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
21	A conceptual framework for integrated STEM education. International Journal of STEM Education, 2016, 3, .	5.0	689
22	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Archives of Pathology and Laboratory Medicine, 2016, 140, 675-677.	2.5	0
23	Two Unrelated Burkitt Lymphomas Seven Years Apart in a Patient With X-Linked Lymphoproliferative Disease Type 1 (XLP1). American Journal of Clinical Pathology, 2016, 146, 248-253.	0.7	5
24	A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2016, 57, 2441-2444.	1.3	20
25	Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing. Annals of Hematology, 2016, 95, 201-210.	1.8	12
26	Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden. Experimental Hematology and Oncology, 2015, 5, 28.	5.0	15
27	Concurrent think-aloud protocols to assess elementary design students. International Journal of Technology and Design Education, 2015, 25, 521-540.	2.6	38
28	A novel approach to quantitating leukemia fusion transcripts by qRT-PCR without the need for standard curves. Experimental and Molecular Pathology, 2015, 99, 104-108.	2.1	4
29	T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. Journal of the American Academy of Dermatology, 2015, 73, 228-236.e2.	1.2	76
30	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	16.8	292
31	A Comparison of Deep Sequencing of <i>TCRG</i> Rearrangements vs Traditional Capillary Electrophoresis for Assessment of Clonality in T-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2014, 141, 348-359.	0.7	41
32	A Quantitative Allele-Specific PCR Test for the BRAF V600E Mutation Using a Single Heterozygous Control Plasmid for Quantitation. Journal of Molecular Diagnostics, 2013, 15, 248-254.	2.8	21
33	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 2013, 121, 489-498.	1.4	187
34	The Number Of Peripheral Blood CD4+CD25+FOXP3+ Regulatory T-Cells Is a Marker Of Response In Patients With JAK2 V617F Positive Myeloproliferative Neoplasms Treated With Pegylated-Interferon-1±. Blood, 2013, 122, 4059-4059.	1.4	1
35	An Inexpensive Ion Torrent-Based Deep Sequencing Assay Demonstrates Marked Superiority Over Sanger Sequencing For Routine Detection Of BCR-ABL1 Kinase Domain Mutations. Blood, 2013, 122, 2722-2722.	1.4	0
36	Salutary Effect of Pegylated Interferona in PV and ET As Evaluated by Quantitation of Pre-JAK2V617F and JAK2V617F-Bearing Stem Cells and Granulocytes and Correlation with Circulating Regulatory T Cells and HSC Cell Cycle Status. Blood, 2012, 120, 807-807.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Contrasting Requirement for Reactive Oxygen Species for the Suppressive Function of Naturally Occurring Regulatory T Cells but Not Induced Regulatory T Cells.. Blood, 2012, 120, 2146-2146.	1.4	0
38	A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation. Journal of Clinical Pathology, 2011, 64, 618-625.	2.0	6
39	Single Center Experience with Screening for JAK2 V617F, cMPL W515L, cMPL W515K, and JAK2 L611V Mutations in MPN. Rarity of JAK2 L611V Does Not Justify Its Routine Screening. Blood, 2011, 118, 5167-5167.	1.4	0
40	Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,. Blood, 2011, 118, 3744-3744.	1.4	0
41	Helios Is Not a Reliable Marker to Distinguish Thymus-Derived Natural Regulatory T Cells From Induced Regulatory T Cells: Stimulation Conditions Influence Helios Expression. Blood, 2011, 118, 2177-2177.	1.4	0
42	Detection of FLT3 Internal Tandem Duplications in Acute Myeloid Leukemia by Targeted Multi-Gene Next Generation Sequencing,. Blood, 2011, 118, 3547-3547.	1.4	0
43	CD4 CD25 Foxp3 regulatory T cells and hematologic malignancies. Frontiers in Bioscience - Scholar, 2010, S2, 980-992.	2.1	35
44	Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Human Pathology, 2009, 40, 405-412.	2.0	11
45	The Ratio of FOXP3+ Regulatory T Cells to Granzyme B+ Cytotoxic T/NK Cells Predicts Prognosis in Classical Hodgkin Lymphoma and Is Independent of bcl-2 and MAL Expression. American Journal of Clinical Pathology, 2007, 128, 958-965.	0.7	106
46	Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leukemia and Lymphoma, 2007, 48, 2403-2411.	1.3	44
47	Increased Tumor Infiltrating FOXP3+ Regulatory T-Cells Are Associated with Improved Survival in Classical Hodgkin Lymphoma.. Blood, 2006, 108, 2265-2265.	1.4	8
48	Molecular Diagnostic Techniques for the Clinical Evaluation of Gliomas. Diagnostic Molecular Pathology, 2005, 14, 1-8.	2.1	27
49	Podocalyxin. American Journal of Clinical Pathology, 2005, 124, 134-142.	0.7	49
50	Podocalyxin : A Marker of Blasts in Acute Leukemia. American Journal of Clinical Pathology, 2005, 124, 134-142.	0.7	2
51	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leukemia Research, 2004, 28, 845-850.	0.8	26
52	Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas. Applied Immunohistochemistry and Molecular Morphology, 2004, 12, 338-341.	1.2	74
53	The Neuropathology of West Nile Virus Meningoencephalitis. American Journal of Clinical Pathology, 2003, 119, 749-753.	0.7	110
54	The Neuropathology of West Nile Virus Meningoencephalitis: A Report of Two Cases and Review of the Literature. American Journal of Clinical Pathology, 2003, 119, 749-753.	0.7	60

#	ARTICLE	IF	CITATIONS
55	The role of sense of community and motivation in the collaborative learning: an examination of the first-year design course. International Journal of Technology and Design Education, 0, , 1.	2.6	6